Core Viewpoint - Citigroup's research report indicates that Fuhong Hanlin is set to reveal the latest data on HLX43 at the World Conference on Lung Cancer (WCLC), which will further demonstrate its potential in treating non-small cell lung cancer (NSCLC) [1] Group 1 - If HLX43 can maintain an objective response rate (ORR) of 35% to 40% and a median progression-free survival (mPFS) of approximately 5.5 months across a larger sample, the data will be highly persuasive [1] - The global study for third-line NSCLC treatment is estimated to start as early as the first half of 2026 [1] Group 2 - Citigroup estimates that the risk-adjusted peak sales for HLX43 could reach approximately $2.3 billion, with potential for further upside if more data is obtained in NSCLC and other indications [1] - The valuation of HLX22 and Serplulimab has not been fully reflected by investors [1] Group 3 - Citigroup upgraded its rating from "Neutral" to "Buy" and raised the target price from HKD 35 to HKD 95 [1]
大行评级｜花旗：大幅上调复宏汉霖目标价至95港元 评级升至“买入”